Evidence map›Paper›PMID 24982180›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2014

Intravenously administered nanoparticles increase survival following blast trauma.

Margaret M Lashof-Sullivan, Erin Shoffstall, Kristyn T Atkins, Nickolas Keane, Cynthia Bir, Pamela VandeVord, Erin B Lavik

Open access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 71 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. The Chemistry of Lyophilized Blood Products.Bioconjugate chemistry · 2018
    Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 1 country.

Margaret M Lashof-SullivanDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106;
Erin ShoffstallDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106;
Kristyn T AtkinsDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106;
Nickolas KeaneDepartment of Biomedical Engineering, Wayne State University, Detroit, MI 48201; and.
Cynthia BirDepartment of Biomedical Engineering, Wayne State University, Detroit, MI 48201; and.
Pamela VandeVordSchool of Biomedical Engineering and Sciences, Virginia Polytechnic Institute and State University, Blacksburg, VA 24061.
Erin B LavikDepartment of Biomedical Engineering, Case Western Reserve University, Cleveland, OH 44106; erin.lavik@case.edu.
Case Western Reserve University · USWayne State University · USVirginia Tech · US

Funding

Clinically Translatable Nanotechnology: Hemostasis and NeuroprotectionDP2OD007338 · OD · CASE WESTERN RESERVE UNIVERSITY · PI LAVIK, ERIN BAKER · 2010 to 2010
$2.4M
NCCDPHP CDC HHS DP20D007338NIH HHS DP2 OD007338
6 · The paper itself

Abstract

Explosions account for 79% of combat-related injuries, leading to multiorgan hemorrhage and uncontrolled bleeding. Uncontrolled bleeding is the leading cause of death in battlefield traumas as well as in civilian life. We need to stop the bleeding quickly to save lives, but, shockingly, there are no treatments to stop internal bleeding. A therapy that halts bleeding in a site-specific manner and is safe, stable at room temperature, and easily administered is critical for the advancement of trauma care. To address this need, we have developed hemostatic nanoparticles that are administered intravenously. When tested in a model of blast trauma with multiorgan hemorrhaging, i.v. administration of the hemostatic nanoparticles led to a significant improvement in survival over the short term (1 h postblast). No complications from this treatment were apparent out to 3 wk. This work demonstrates that these particles have the potential to save lives and fundamentally change trauma care.

Indexed as

NanoparticlesAdministration, IntravenousAnimalsBlast InjuriesDisease Models, AnimalHemorrhageHemostaticsMaleMiceTime FactorsWarfareHemostaticsclotlungmedicpolytraumasynthetic platelets

Identifiers

PMID24982180
PMCPMC4104920
OpenAlexW2009259358

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.